<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618275</url>
  </required_header>
  <id_info>
    <org_study_id>7635</org_study_id>
    <nct_id>NCT05618275</nct_id>
  </id_info>
  <brief_title>Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS</brief_title>
  <acronym>BKV-Allograf</acronym>
  <official_title>Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the University Hospital of Strasbourg (HUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BK virus (BKV) belongs to the Polyomaviridae family. The primary infection, generally&#xD;
      asymptomatic, occurs during childhood. The virus then persists in latent form in the body,&#xD;
      mainly in the epithelial cells of the kidney and urinary tract. Cellular immunosuppression&#xD;
      favors BKV replication. It is responsible for pathologies of the renal-urinary tract such as&#xD;
      BKV-associated nephropathy (BKVAN) in kidney transplant recipients, hemorrhagic cystitis (HC)&#xD;
      in hematopoietic stem cell (HSC) recipients or ureteral stenosis.&#xD;
&#xD;
      To date, there is no specific antiviral treatment against BKV. The management of patients is&#xD;
      essentially symptomatic and requires a multidisciplinary approach. It is therefore necessary&#xD;
      to identify early prognostic markers for the occurrence of CH and to develop new therapeutic&#xD;
      strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of the role of anti-BKV neutralizing antibodies in HSCT patients in the pediatric oncology-hematology department of the HUS</measure>
    <time_frame>Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>BK Virus Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HSC allograft patient managed by the pediatric oncology-hematology service of the HUS,&#xD;
        between 01/01/2015 and 31/12/2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patient aged 18 to 19 years&#xD;
&#xD;
          -  Minor patient (from birth to 17 years old)&#xD;
&#xD;
          -  HSC allograft patient managed by the pediatric oncology-hematology service of the HUS,&#xD;
             between 01/01/2015 and 31/12/2019&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of the patient (or parental authority holders) to participate in the study&#xD;
&#xD;
          -  Biological resources from a patient who does not meet all inclusion criteria&#xD;
&#xD;
          -  Patient deprived of liberty or under court protection&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>19 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, PharmD</last_name>
    <phone>33 3 69 55 14 38</phone>
    <email>samira.fafi-kremer@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service Laboratoire de Virologie - PTM - CHU de Strasbourg - France</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <phone>33 3 69 55 14 38</phone>
      <email>samira.fafi-kremer@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine PAILLARD, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie VELAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SEVERAC, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BK virus infection</keyword>
  <keyword>Neutralizing antibodies</keyword>
  <keyword>Hematopoietic stem cell</keyword>
  <keyword>Polyomaviridae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

